Business Context and Reporting Period
Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2023
Reporting Period: Third quarter ended September 30, 2023
Context: The filing serves to announce financial results for the third quarter of 2023 and provide corporate updates via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release containing the specific financial data but does not list the numerical values within this document.
- Revenue, Profit, Cash Flow, Margins: Not provided in the filing text; contained in the referenced press release (Exhibit 99.1).
- Debt and Liquidity: Not provided in the filing text; contained in the referenced press release (Exhibit 99.1).
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only indicates that such results were announced in the accompanying press release.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release with corporate updates, but the specific content of the outlook or commentary is not included in this text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2023) for actual Q3 2023 revenue, net loss, and cash position figures.
- Verify the specific "corporate updates" mentioned in the press release for potential strategic shifts or operational milestones.
- Confirm the company's status as an "Emerging Growth Company" and its election regarding extended transition periods for accounting standards.
- Check the Nasdaq Global Select Market listing status for the common stock (Symbol: SPRB).